Shanghai-based biopharmaceutical company Harbour BioMed today announced successful completion of a Series B+ round financing of US$75 million. New investors SK Holdings, Greater Bay Area Fund, Efung Capital, Zheshang Venture Capital and Zhejiang University Future Capital and JT New Century, as well as existing investors Legend Capital, AdvanTech and GIC participated in this round. The company previously completed an US$85 million Series B financing in August 2018.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
